U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07201675) titled 'Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment' on Sept. 07.
Brief Summary: This is a phase II clinical study to evaluate the efficacy of RC48-ADC combined with toripalimab bladder-sparing therapy.
The RC48-ADC dose in this study is 2.0 mg/kg Q2W and toripalimab is 3 mg/kg Q2W.
This study plans to enroll 59 participants. The participants will start drug therapy within 2 weeks after the first diagnostic resection in the first stage, receiving RC48-ADC combined with toripalimab 3 times. At the 8th week after enrollment, the second stage of cystectomy was performed, and RC48-ADC combined with toripalim...